The new campaign stars former NFL quarterback Alex Smith, whose leg injury during a 2018 game led to a case of ...

Journavx received FDA approval, the agency announced on Thursday, Jan. 30. The drug developed by Boston-based Vertex Pharmaceuticals blocks sodium channels in the peripheral nervous system ...

The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

On VRTX's first-quarter earnings call, investors are likely to focus on the launch preparation for Alyftrek (vanza triple) ...

On January 30th, in a landmark decision that could reshape the way acute pain is treated in the United States, the FDA approved suzetrigine (brand name, Journavx), a first-in-class non-opioid ...

After a sudden pause of steep "reciprocal" tariffs by the Trump administration (but not a pause on all tariffs instituted) on Wednesday, the index rebounded strongly. As of Thursday afternoon, it had ...

New non-opioid pain killer get FDA approval for acute pain. Patients are taking note. Also demonstrated efficacy, just not ...

Heading into 2025, an even bigger game changer for the company may be Journavx, approved in January by the FDA as the first oral non-opioid painkiller in its class. Journavx taps into a massive ...

Notably, on January 30, the FDA approved JOURNAVX for the treatment of adults with moderate-to-severe acute pain. The analyst opines that the outpatient market offers a strong opportunity for ...